Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): Extended follow-up from the phase 3, randomised, open-label study Journal Article
| Authors: | Choueiri, T. K.; Eto, M.; Motzer, R.; De Giorgi, U.; Buchler, T.; Basappa, N. S.; Méndez-Vidal, M. J.; Tjulandin, S.; Park, S. H.; Melichar, B.; Hutson, T.; Alemany, C.; McGregor, B.; Powles, T.; Grünwald, V.; Alekseev, B.; Rha, S. Y.; Kopyltsov, E.; Kapoor, A.; Alonso Gordoa, T.; Goh, J. C.; Staehler, M.; Merchan, J. R.; Xie, R.; Perini, R. F.; Mody, K.; McKenzie, J.; Porta, C. G. |
| Article Title: | Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): Extended follow-up from the phase 3, randomised, open-label study |
| Journal Title: | Lancet Oncology |
| Volume: | 24 |
| Issue: | 3 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2023-03-01 |
| Start Page: | 228 |
| End Page: | 238 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(23)00049-9 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PUBMED: | 36858721 |
| DOI/URL: | |
| Notes: | Erratum issued, see DOI: 10.1016/S1470-2045(23)00117-1 -- Accession Number: 162110827 -- Entry Date: In Process -- Revision Date: 20230301 -- Publication Type: Article -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 100957246. -- Source: Cinahl |
